See the DrugPatentWatch profile for Zejula
The cost of Zejula (niraparib) can vary significantly depending on several factors, including insurance coverage, pharmacy, and geographic location. While specific pricing is not publicly listed by the manufacturer, available information suggests that without insurance, the drug can be quite expensive.
What is the typical out-of-pocket cost for Zejula?
For patients without insurance, the list price of Zejula can be thousands of dollars per month. For instance, one estimate places the monthly cost at around \$9,688 [1]. However, most patients utilize insurance to reduce their out-of-pocket expenses.
How does insurance affect Zejula pricing?
Insurance plans often provide coverage for Zejula, substantially lowering the cost for patients. The exact copay or coinsurance will depend on the specific insurance policy. Manufacturers often offer patient assistance programs to help eligible individuals manage their medication costs. For Zejula, GSK, the manufacturer, offers a ZEJULA Savings Program that may reduce out-of-pocket costs to as low as \$0 per month for eligible commercially insured patients [2]. Eligibility requirements and program details can be found on the manufacturer's website.
Are there patient assistance programs available for Zejula?
Yes, patient assistance programs are available to help reduce the financial burden of Zejula. The ZEJULA Savings Program is one such option, providing support for eligible commercially insured patients [2]. Details on how to apply and the specific benefits offered can typically be obtained through the manufacturer or a healthcare provider.
How does Zejula's cost compare to other PARP inhibitors?
Zejula is a PARP inhibitor used for the maintenance treatment of certain types of ovarian, fallopian tube, and primary peritoneal cancer. Other PARP inhibitors, such as olaparib (Lynparza) and rucaparib (Rubraca), are also available. The cost of these drugs can be comparable, and patient out-of-pocket expenses will also be influenced by insurance coverage and available assistance programs for each medication.
When does Zejula's patent expire?
Understanding patent expiry is crucial for potential generic competition, which can impact drug pricing. According to DrugPatentWatch.com, the patent situation for niraparib involves multiple patents and potential exclusivities [3]. Details on specific patent expiry dates for Zejula are complex and may be subject to legal challenges.
What is the mechanism of action for Zejula?
Zejula is a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in DNA repair. By inhibiting PARP, Zejula prevents cancer cells from repairing their damaged DNA, leading to cell death, particularly in cancers with existing DNA repair deficiencies, such as those with BRCA mutations [4].
What are the approved uses for Zejula?
Zejula is approved for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to first-line platinum-based chemotherapy [4]. It is also approved for adult patients with recurrent, susceptible to platinum-based chemotherapy, epithelial ovarian, fallopian tube, or primary peritoneal cancer [4].
---
Sources:
[1] https://www.goodrx.com/niraparib
[2] https://www.zejula.com/savings-and-support/
[3] https://drugpatentwatch.com/
[4] https://www.zejula.com/ [Accessed on date of generation]